May 3, 2016 SOURCE: REGEN BIOPHARMA INC.

Regen BioPharma Receives Preliminary Clinical Data from Pan Am Cancer Center Regarding Their HemaXellerate Study in Cancer Patients.  Initial results from Pan Am Cancer Center suggest positive impact from HemaXellerate on bone marrow suppression with no toxicity